新闻中心

Engineered cancer cells can fight primary and metastatic cancer

作者:Brigham and Women's Hospital

时间 :2018/7/11 0:00:00

Boston, MA -- What if cancer cells could be re-engineered to turn against their own kind? A new study led by researchers at Brigham and Women's Hospital leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer. Results are published in Science Translational Medicine.

"This is just the tip of the iceberg," said corresponding author Khalid Shah MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). "Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient's own cancer cells and use them to treat cancer. We think this has many implications and could be applicable across all cancer cell types."

The new approach capitalizes on cancer cells' self-homing ability - the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.

The team developed and tested two techniques to harness the power of cancer cells. The "off the shelf" technique used pre-engineered tumor cells that would need to be matched to a patient's HLA phenotype (essentially, a person's immune fingerprint). The "autologous" approach used CRISPR technology to edit the genome of a patient's cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.

To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and metastatic cancer in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a "kill switch" that could be activated after treatment - PET imaging showed that this kill switch worked to eliminate the cells.

"Our study demonstrates the therapeutic potential of using engineered tumor cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers," said Shah.

###

This study was supported by James S. McDonnell Foundation and Departmental funds.

<< 上一篇:ASHG honors Sekar Kathiresan with 2018 Curt Stern Award 下一篇:Taming a fatal blood cancer>>
技术支持:北京华宇星航国际教育科技有限公司 豫ICP备17016808号

人工智能在线咨询

智能在线咨询 X

关于我们

该服务平台支持关键词检索、文献题名检索(准确题名)、文献DOI号检索、作者检索。当查询题名返回的结果无法下载全文数据或查询不到时,请找到所查文献DOI号后再次查询。查询结果会在10秒内返回, 24小时不间断的提供文献查询服务。

微信端

人工智能在线咨询